Vascular endothelial growth factor in eye disease

J. S. Penn, A. Madan, Ruth B Caldwell, Manuela Bartoli, Robert William Caldwell, M. E. Hartnett

Research output: Contribution to journalReview article

354 Citations (Scopus)

Abstract

Collectively, angiogenic ocular conditions represent the leading cause of irreversible vision loss in developed countries. In the US, for example, retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration are the principal causes of blindness in the infant, working age and elderly populations, respectively. Evidence suggests that vascular endothelial growth factor (VEGF), a 40 kDa dimeric glycoprotein, promotes angiogenesis in each of these conditions, making it a highly significant therapeutic target. However, VEGF is pleiotropic, affecting a broad spectrum of endothelial, neuronal and glial behaviors, and confounding the validity of anti-VEGF strategies, particularly under chronic disease conditions. In fact, among other functions VEGF can influence cell proliferation, cell migration, proteolysis, cell survival and vessel permeability in a wide variety of biological contexts. This article will describe the roles played by VEGF in the pathogenesis of retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration. The potential disadvantages of inhibiting VEGF will be discussed, as will the rationales for targeting other VEGF-related modulators of angiogenesis.

Original languageEnglish (US)
Pages (from-to)331-371
Number of pages41
JournalProgress in Retinal and Eye Research
Volume27
Issue number4
DOIs
StatePublished - Jul 1 2008

Fingerprint

Eye Diseases
Vascular Endothelial Growth Factor A
Retinopathy of Prematurity
Macular Degeneration
Diabetic Retinopathy
Angiogenesis Modulating Agents
Blindness
Developed Countries
Neuroglia
Proteolysis
Cell Movement
Permeability
Cell Survival
Glycoproteins
Chronic Disease
Cell Proliferation
Population

Keywords

  • Age-related macular degeneration
  • Angiogenesis
  • Diabetic retinopathy
  • Retina
  • Retinopathy of prematurity
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Vascular endothelial growth factor in eye disease. / Penn, J. S.; Madan, A.; Caldwell, Ruth B; Bartoli, Manuela; Caldwell, Robert William; Hartnett, M. E.

In: Progress in Retinal and Eye Research, Vol. 27, No. 4, 01.07.2008, p. 331-371.

Research output: Contribution to journalReview article

@article{da179fbeaad244fa84c91ee2abb3547f,
title = "Vascular endothelial growth factor in eye disease",
abstract = "Collectively, angiogenic ocular conditions represent the leading cause of irreversible vision loss in developed countries. In the US, for example, retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration are the principal causes of blindness in the infant, working age and elderly populations, respectively. Evidence suggests that vascular endothelial growth factor (VEGF), a 40 kDa dimeric glycoprotein, promotes angiogenesis in each of these conditions, making it a highly significant therapeutic target. However, VEGF is pleiotropic, affecting a broad spectrum of endothelial, neuronal and glial behaviors, and confounding the validity of anti-VEGF strategies, particularly under chronic disease conditions. In fact, among other functions VEGF can influence cell proliferation, cell migration, proteolysis, cell survival and vessel permeability in a wide variety of biological contexts. This article will describe the roles played by VEGF in the pathogenesis of retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration. The potential disadvantages of inhibiting VEGF will be discussed, as will the rationales for targeting other VEGF-related modulators of angiogenesis.",
keywords = "Age-related macular degeneration, Angiogenesis, Diabetic retinopathy, Retina, Retinopathy of prematurity, Vascular endothelial growth factor",
author = "Penn, {J. S.} and A. Madan and Caldwell, {Ruth B} and Manuela Bartoli and Caldwell, {Robert William} and Hartnett, {M. E.}",
year = "2008",
month = "7",
day = "1",
doi = "10.1016/j.preteyeres.2008.05.001",
language = "English (US)",
volume = "27",
pages = "331--371",
journal = "Progress in Retinal and Eye Research",
issn = "1350-9462",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Vascular endothelial growth factor in eye disease

AU - Penn, J. S.

AU - Madan, A.

AU - Caldwell, Ruth B

AU - Bartoli, Manuela

AU - Caldwell, Robert William

AU - Hartnett, M. E.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Collectively, angiogenic ocular conditions represent the leading cause of irreversible vision loss in developed countries. In the US, for example, retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration are the principal causes of blindness in the infant, working age and elderly populations, respectively. Evidence suggests that vascular endothelial growth factor (VEGF), a 40 kDa dimeric glycoprotein, promotes angiogenesis in each of these conditions, making it a highly significant therapeutic target. However, VEGF is pleiotropic, affecting a broad spectrum of endothelial, neuronal and glial behaviors, and confounding the validity of anti-VEGF strategies, particularly under chronic disease conditions. In fact, among other functions VEGF can influence cell proliferation, cell migration, proteolysis, cell survival and vessel permeability in a wide variety of biological contexts. This article will describe the roles played by VEGF in the pathogenesis of retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration. The potential disadvantages of inhibiting VEGF will be discussed, as will the rationales for targeting other VEGF-related modulators of angiogenesis.

AB - Collectively, angiogenic ocular conditions represent the leading cause of irreversible vision loss in developed countries. In the US, for example, retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration are the principal causes of blindness in the infant, working age and elderly populations, respectively. Evidence suggests that vascular endothelial growth factor (VEGF), a 40 kDa dimeric glycoprotein, promotes angiogenesis in each of these conditions, making it a highly significant therapeutic target. However, VEGF is pleiotropic, affecting a broad spectrum of endothelial, neuronal and glial behaviors, and confounding the validity of anti-VEGF strategies, particularly under chronic disease conditions. In fact, among other functions VEGF can influence cell proliferation, cell migration, proteolysis, cell survival and vessel permeability in a wide variety of biological contexts. This article will describe the roles played by VEGF in the pathogenesis of retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration. The potential disadvantages of inhibiting VEGF will be discussed, as will the rationales for targeting other VEGF-related modulators of angiogenesis.

KW - Age-related macular degeneration

KW - Angiogenesis

KW - Diabetic retinopathy

KW - Retina

KW - Retinopathy of prematurity

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=48549088705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48549088705&partnerID=8YFLogxK

U2 - 10.1016/j.preteyeres.2008.05.001

DO - 10.1016/j.preteyeres.2008.05.001

M3 - Review article

C2 - 18653375

AN - SCOPUS:48549088705

VL - 27

SP - 331

EP - 371

JO - Progress in Retinal and Eye Research

JF - Progress in Retinal and Eye Research

SN - 1350-9462

IS - 4

ER -